AstraZeneca | GenomeWeb

AstraZeneca

The molecular diagnostics firm said it will submit its BRACAnalysis CDx alongside AstraZeneca's Lynparza to Japan's Pharmaceuticals and Medical Devices Agency.



The update includes several key initiatives such as a liquid biopsy database, a DoD-led longitudinal study, and NCI cloud collaborations with Amazon and Microsoft.

The test can now be used to detect EGFR mutations in tissue and blood for lung cancer patients considering treatment with the tyrosine kinase inhibiting drugs Tarceva and Tagrisso. 

The partners are working together to advance research into the role of epigenetics in respiratory diseases such as asthma and COPD.

The STARNET study found that cardiometabolic disease risk loci share cis- and trans-gene regulation.

The resource will offer easy access to an inventory of vendors with patient-derived xenograph models as well as associated molecular data for oncology drug discovery projects.

Drug developers and genetic testing firms are contemplating how best to share variant classification data while protecting their commercial interests.

Lynparza is just the start of an expansive portfolio of treatments targeting DNA damage response that AstraZeneca said it will advance with companion tests.

The assay will detect multiple classes of genomic alterations across a range of genes involved in homologous recombination repair.

The firm also said that Roche started selling FoundationOne in Israel, Austria, Germany, Switzerland, Brazil, Canada, and Singapore last month.

Pages

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.